Skip to main navigation

About People Science Pipeline Patients Investors Careers

Overview
Vision & Values
Impact
Founder's Letter
Contact

Overview
Leadership Team
Board of Directors
Scientific Advisory Board
R&D Advisory Board

RAS/MAPK Pathway
MAPKlamp & More
Presentations & Publications

Pipeline
Programs
Clinical Trials

Patients & Caregivers
Clinical Trials

Corporate Overview
News & Events
Stock Information
Corporate Governance
Financial Information
Investor Resources

Dynamic Culture
Values & Attributes
Competitive Benefits
Open Positions

Stay in Touch

858.465.6511
info@erasca.com

News & Events

News Releases
Erasca in the News
Events
Presentations

News Releases

Year

11.28.2023

Erasca Achieves Key Milestones for Naporafenib and ERAS-801 Programs and Extends Cash Runway

11.09.2023

Erasca Reports Third Quarter 2023 Financial Results and Business Updates

11.08.2023

Erasca to Present at Upcoming Investor Conferences in November

09.19.2023

Erasca to Present at the Cantor Global Healthcare Conference

09.05.2023

Erasca to Present at the Morgan Stanley 21st Annual Global Healthcare Conference

08.29.2023

Erasca Doses First Patient in SEACRAFT-1 Phase 1b Trial Evaluating Naporafenib Plus Trametinib in Patients with RAS Q61X Solid Tumors

08.10.2023

Erasca Reports Second Quarter 2023 Financial Results and Business Updates

06.22.2023

Erasca Granted FDA Orphan Drug Designation for CNS-Penetrant EGFR Inhibitor ERAS-801 for the Treatment of Malignant Glioma

06.05.2023

Erasca Provides Update on Clinical Program for ERK Inhibitor ERAS-007 and Refines Pipeline

06.01.2023

Erasca to Present at Upcoming Investor Conferences

Pagination

Current page 1
Page 2
Page 3
Next page
Last page

Displaying 1 - 10 of 24

Site - Investor Tools

Contact Us

info@erasca.com

Location

ERASCA, INC.

3115 Merryfield Row

Suite 300

San Diego, CA 92121

Terms of Use
Privacy Policy

© 2021 Erasca™, Inc. All rights reserved.